Liposomes as targeted drug delivery systems in the treatment of breast cancer

Journal of Drug Targeting

Volumn 14, Issue 5, 2006, Pages 301-310

  Sharma, G ^a   Anabousi, S ^b   Ehrhardt, C ^b,c   Ravi Kumar, M N V ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b SAARLAND UNIVERSITY   (Germany)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

particle therapy; Anti HER 2 therapy; E1A1 gene; Hyperthermia; VIP receptors

Indexed keywords

ACTINIUM 225; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CAMPTOTHECIN; CISPLATIN; CREMOPHOR; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; E1A PROTEIN; GEMCITABINE; IMMUNOLIPOSOME; LIPOSOME; MACROGOL; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PEPTIDE; PHOSPHATIDYLETHANOLAMINE; POLYGLUTAMIC ACID; POLYMER; POLYSORBATE 80; RADIOISOTOPE; TAXANE DERIVATIVE; TRASTUZUMAB; UNINDEXED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

ALOPECIA; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST CARCINOGENESIS; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER TISSUE; CARDIOTOXICITY; CELL LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG EXTRAVASATION; DRUG HYPERSENSITIVITY; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TARGETING; GASTROINTESTINAL TOXICITY; HUMAN; HYPERTHERMIC THERAPY; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTRON CAPTURE THERAPY; PH; PRIORITY JOURNAL; REVIEW; SKIN NECROSIS; SOLID TUMOR; STOMATITIS; TISSUE PRESSURE; TUMOR VASCULARIZATION; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BORON NEUTRON CAPTURE THERAPY; BREAST NEOPLASMS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; LIPOSOMES; MICE;

EID: 33746852068     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860600809112     Document Type: Review

References (94)

1. Allen, TM and Sapra, P and Moase, E and Moreira, J and Iden, D. (2002) Adventures in targeting J Liposome Res, 12, pp. 5-12.
2. Anabousi, S and Laue, M and Lehr, CM and Bakowsky, U and Ehrhardt, C. (2005) Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy Eur J Pharm Biopharm, 60, pp. 295-303.
3. Banerjee, R. (2001) Liposomes: Applications in medicine J Biomater Appl, 16, pp. 3-21.
4. Bangham, AD and Standish, MM and Watkins, JC. (1965) Diffusion of univalent ions across lamellae of swollen phospholipids J Mol Biol, 13, pp. 238-252.
5. Barth, RF. (2003) A critical assessment of boron neutron capture therapy: An overview J Neurooncol, 62, pp. 1-5.
6. Batist, G and Ramakrishnan, G and Rao, CS and Chandrasekharan, A and Gutheil, J and Guthrie, T and Shah, P and Khojasteh, A and Nair, MK and et al. (2001) Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer J Clin Oncol, 19, pp. 1444-1454.
7. Berger, M and Shankar, V and Vafai, A. (2002) Therapeutic applications of monoclonal antibodies Am J Med Sci, 324, pp. 14-30.
8. Bhatia, A and Kumar, R and Katare, OP. (2004) Tamoxifen in topical liposomes: Development, characterization and in-vitro evaluation J Pharm Pharm Sci, 7, pp. 252-259.
9. Blackwell, KL and Dewhirst, MW and Liotcheva, V and Snyder, S and Broadwater, G and Bentley, R and Lal, A and Riggins, G and Anderson, S and Vrendenburgh, J and et al. (2004) HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors Clin Cancer Res, 10, pp. 4083-4088.
10. Budker, V and Gurevich, V and Hagstrom, JE and Bortzov, F and Wolff, JA. (1996) pH-sensitive, cationic liposomes: A new synthetic virus-like vector Nat Biotechnol, 14, pp. 760-764.
11. Campos, S. (2003) Liposomal anthracyclines: Adjuvant and neoadjuvant therapy for breast cancer Oncologist, 8, pp. 10-16.
12. Campbell, PI. (1983) Toxicity of some charged lipids used in liposome preparation Cytobios, 37, pp. 21-26.
13. Coombs, NJ and Taylor, R and Wilcken, N and Boyages, J. (2005) HRT and breast cancer: Impact on population risk and incidence Eur J Cancer, 41, pp. 1775-1781.
14. Dagar, S and Krishnadas, A and Rubinstein, I and Blend, MJ and Onyuksel, H. (2003) VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: In vivo studies J Control Release, 91, pp. 123-133.
15. Denny, WA. (1996) The design of selectively activated prodrugs for cancer chemotherapy Curr Pharm Des, 2, pp. 281.
16. Derycke, ASL and Witte, PAM. (2004) Liposomes for photodynamic therapy Adv Drug Deliv Rev, 56, pp. 17-30.
17. Doroshaw, JH.(1996) Anthracyclines and antracenediones, in cancer chemotherapy and biotherapy: Principles and practice. Philadelphia: Lippincott-Raven Publishers.
18. Drummond, DC and Zignani, M and Leroux, JC. (2000) Current status of pH sensitive liposomes in drug delivery Prog Lipid Res, 39, pp. 409-460.
19. Drummond, DC and Meyer, O and Hong, K and Kirpotin, DB and Papahadjopoulos, D. (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors Pharmacol Rev, 51, pp. 691-744.
20. Gabizon, AA. (1992a) Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS Cancer Res, 52, pp. 891-896.
21. Gabizon, AA. (1992b) Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes Cancer Res, 15, pp. 891-896.
22. Gabizon, AA and Shmeeda, H and Horowitz, AT and Zalipsky, S. (2004) Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates Adv Drug Deliv Rev, 56, pp. 1177-1192.
23. Gabizon, AA and Shiota, R and Papahadjopoulos, D. (1989) Pharmacokinetics and tissue distribution of doxorubicin encapsulated in stable liposomes with long circulation times J Natl Cancer Inst, 81, pp. 1484-1488.
24. Gokhale, PC and Zhang, C and Newsome, JT and Pei, J and Ahmad, I and Rahman, A and Dritschilo, A and Kasid, UN. (2002) Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome Clin Cancer Res, 8, pp. 3611-3621.
25. Goldenberg, MM. (1999) Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer Clin Ther, 21, pp. 309-318.
26. Goyal, P and Goyal, K and Kumar, SGV and Singh, A and Katare, OP and Mishra, DN. (2005) Liposomal drug delivery systems: Clinical applications Acta Pharm, 55, pp. 1-25.
27. Gregoriadis, G. (1991) Overview of liposomes J Antimicrob Chemother, 28, pp. 39-48.
28. Gregoriadis, G. (1994) Liposomes as immunoadjuvants and vaccine carriers: Antigen entrapment J Immunol Methods, 4, pp. 210-216.
29. Gregoriadis, G and Florence, AT. (1991) Liposomes and cancer therapy Cancer Cells, 4, pp. 144-146.
30. Harris, J and Lippman, M and Morrow, M and Osborne, C.(2000) Diseases of the breast. Philadelphia, PA: Lippincott Williams & Wilkins.
31. Harris, L and Winer, E and Batist, G and Rovira, D and Navaria, R and Lee, L. (1998) Phase III study of TLC D-99 (liposome encapsulated doxorubicin) vs. free doxorubicin (DOX) in patients with metastatic breast carcinoma (MBC) Proc Am Soc Clin Oncol, 17, pp. 124.
32. Hauck, ML and Dewhirst, MW and Bigner, DD and Zalutsky, ML. (1997) Local hyperthermia improves uptake of a chimeric monoclonal antibody in a subcutaneous xenograft model Clin Cancer Res, 3, pp. 63-70.
33. Hewitt, M and Breen, N and Devesa, S. (1999) Cancer prevalence and survivorship issues: Analysis of the 1992 national health interview survey J Natl Cancer Inst, 91, pp. 1480-1486.
34. Hobbs, SK and Monsky, WL and Yuan, F and Roberts, WG and Griffith, L and Torchilin, VP and Jain, RK. (1998) Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment Proc Natl Acad Sci, 95, pp. 4607-4612.
35. Hortobaygi, GN. (1998) Drug thearpy N Engl J Med, 339, pp. 974-984.
36. Humm, JL and Chin, LM. (1993) A model of cell inactivation by alpha-particle internal emitters Radiat Res, 134, pp. 143-150.
37. Hung, MC and Matin, A and Zhang, Y and Xing, X and Sorgi, F and Huang, L and Dihua, Y. (1995) HER-2/neu-targeting gene therapy-a review Gene, 159, pp. 65-71.
38. Immordino, ML and Brusa, P and Arpicco, S and Stella, B and Dosio, F and Cattel, L. (2003) Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel J Control Release, 91, pp. 417-429.
39. Jain, RK. (1999) Transport of molecules, particles, and cells in solid tumors Annu Rev Biomed Eng, 1, pp. 241-263.
40. Jardines, L and Callans, LS and Torosian, MH. (1993) Recurrent breast cancer: Presentation, diagnosis, and treatment Semin Oncol, 20, pp. 538-547.
41. Jones, M. (1994) Carbohydrate mediated liposomal targeting and drug delivery Adv Drug Deliv Rev, 13, pp. 215-250.
42. Jurcic, JG and Larson, SM and Sgouros, G. (2002) Targeted alpha-particle immunotherapy for myeloid leukemia Blood, 100, pp. 1233-1239.
43. Koukourakis, MI and Koukouraki, S and Giatromanolaki, A. (2000) High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas Acta Oncol, 39, pp. 207-211.
44. Kozubek, A and Gubernator, J and Przeworska, E and Stasiuk, M. (2000) Liposomal drug delivery, a novel approach: PLARosomes Acta Biochim Pol, 47, pp. 639-649.
45. Lag R, Kosary CKL, Hankey BF. 1999. SEER Cancer Statistics Review 1973-1996, National Cancer Institute, Bethesda, MD USA, http://seer.cancer.gov/csr/1973_1996/
46. Langner, M and Kral, TE. (1999) Liposome-based drug delivery systems Pol J Pharmacol, 51, pp. 211-222.
47. Legendre, JY and Szoka, FC. (1992) Delivery of plasmid DNA into mammalian cell lines using pH-sensitive liposomes: Comparison with cationic liposomes Pharm Res, 9, pp. 1235-1242.
48. Leopold, KA and Dewhirst, MW and Samulski, TV and Harrelson, J and Tucker, JA and George, SL and Dodge, RK and Grant, W and Clegg, S and Prosnitz, LR and et al. (1992) Relationship among tumor temperature, treatment time, and histopathological outcome using preoperative hyperthermia with radiation in soft tissue sarcomas Int J Radiat Oncol Biol Phys, 22, pp. 989-998.
49. Menezes, DEL and Hudon, N and Cintosh, NM and Mayer, N. (2000) Pharmacokinetic properties associated with the therapeutics of Bcl-2 antisense oligonucleotide G3139 combined with free and liposomal Doxorubicin Clin Cancer Res, 6, pp. 2891-2902.
50. Minotti, G and Menna, P and Salvatorelli, E and Cairo, G and Gianni, L. (2004) Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity Pharmacol Rev, 56, pp. 185-229.
51. Muggia, FM. (1999) Doxorubicin-polymer conjugates: Further demonstration of the concept of enhanced premeability and retention Clin Cancer Res, 5, pp. 7-8.
52. Mymryk, JS. (1996) Tumor suppressive properties of the adenovirus 5 E1A oncogene Oncogene, 13, pp. 1581-1589.
53. Needham, D and Anyarambhatla, G and Kong, G and Dewhirst, MW. (2000) A new temperature-sensitive liposome for use with mild hyperthermia: Characterization and testing in a human tumor xenograft model Cancer Res, 60, pp. 1197-1201.
54. Needham, D and Dewhirst, MW. (2001) The development and testing of a new temperature sensitive drug delivery system for the treatment of solid tumors Adv Drug Deliv Rev, 53, pp. 285-305.
55. Neumann, E and Engelsberg, A and Decker, J and Storkel, S and Jaeger, E and Huber, C and Seliger, B. (1998) Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: Candidates for T-cell-based immunotherapies? Cancer Res, 58, pp. 4090-4095.
56. Pal, A and Ahmad, A and Khan, S and Sakabe, I and Zhang, C and Kasid, U and Ahmad, I. (2005) Systemic delivery of Raf-si RNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer Int J Oncol, 26, pp. 1087-1091.
57. Papahadjopoulos, D and Gabizon, AA. (1987) Targeting of liposomes to tumor cells in vivo Ann NY Acad Sci, 507, pp. 64-74.
58. Parbhoo, S.(2005) Breast cancer overview. London: Cancerkin, Royal Free Hospital.
59. Park, JW. (2002a) Liposome-based drug delivery in breast cancer treatment Breast Cancer Res, 4, pp. 95-99.
60. Park, JW. (2002b) The potential of drug-carrying immunoliposomes as anticancer agents Clin Cancer Res, 8, pp. 955-956.
61. Park, JW and Hong, K and Carter, P and Asgari, H and Guo, LY and Keller, GA and Wirth, C and Shalaby, R and Kotts, C and Wood, WI and et al. (1995) Development of anti-p185HER2 immunoliposomes for cancer therapy Proc Natl Acad Sci, 92, pp. 1327-1331.
62. Park, JW and Hong, K and Kirpotin, DB and Shalaby, R and Colbern, G and Baselga, J and Shao, Y and Nielsen, UB and Marks, JD and Moore, D and et al. (2002) Anti-HER2 immunoliposomes: Enhanced anticancer efficacy due to targeted delivery Clin Cancer Res, 8, pp. 1172-1181.
63. Park, JW and Kirpotin, DB and Hong, K and Shalaby, R and Shao, Y and Nielsen, UB and Marks, JD and Papahadjopoulos, D and Benz, CC. (2001) Tumor targeting using anti-her2 immunoliposomes J Control Release, 74, pp. 95-113.
64. Parkin, DM and Bray, F and Ferlay, J and Pisani, P. (2002) Global cancer statistics, 2002 CA Cancer J Clin, 55, pp. 74-108.
65. Parr, MJ and Masin, D and Cullis, P and Bally, MB. (1997) Accumulation of liposomal lipid and encapsulated doxorubicin in murine lewis lung carcinomas: The lack of beneficial effects by coating liposomes with poly(ethylene glycol) J Pharmacol Exp Ther, 280, pp. 1319-1327.
66. Patil, SD and Rhodes, DG and Burgess, DJ. (2004) Anionic liposomal delivery system for DNA transfection AAPS J, 6, pp. 1-10.
67. Patil, SD and Rhodes, DG and Burgess, DJ. (2005) DNA-based therapeutics and DNA delivery systems: A comprehensive review AAPS J, 7, pp. 61-77.
68. Phillips, WT and Rudolph, AS and Goins, B and Timmons, JH and Klipper, R and Blumhardt, R. (1992) A simple method for producing a technetium-99m-labeled liposome which is stable in vivo Int J Rad Appl Instrum B, 19, pp. 539-547.
69. Ranson, MR and Carmichael, J and Byrne, KO and Stewart, S and Smith, D and Howell, A. (1997) Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial J Clin Oncol, 15, pp. 3185-3191.
70. Reinhold, HS and Endrich, B. (1986) Tumor microcirculation as a target for hyperthermia Int J Hyperthermia, 2, pp. 111-137.
71. Reubi, JC. (1996) In vitro identification of VIP receptors in human tumors: Potential clinical implications Ann NY Acad Sci, 805, pp. 753-759.
72. Rivera, E and Valero, V and Syrewicz, L and Rahman, Z and Esteva, FL and Theriault, RL and Rosales, MM and Booser, D and Murray, JL and Bast, RC and et al. (2001) Phase 1 study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer J Clin Oncol, 19, pp. 1716-1722.
73. Rooijen van, N and Nieuwmegen van, R. (1980) Liposomes in immunology: Multilamellar phosphatidylcholine liposome as a simple biodegradable and harmless adjuvant without any immunogenic activity of its own Immunol Commun, 9, pp. 243-256.
74. Sharma, A and Straubinger, RM and Ojima, I and Bernacki, RJ. (1995) Antitumor efficacy of taxane liposomes on a human ovarian tumour xenograft in nude athymic mice J Pharm Sci, 84, pp. 1400-1404.
75. Shaughnessy, JO. (2003) Liposomal anthracyclines for breast cancer: Overview Oncologist, 8, pp. 1-2.
76. Sihorkar, V and Vyas, SP. (2001) Potential of polysaccharide anchored liposomes in drug delivery, targeting and immunization J Pharm Pharm Sci, 4, pp. 138-158.
77. Slamon, DJ and Leyland-Jones, B and Shak, S. (2001) Usr of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med, 344, pp. 783-792.
78. Sofou, S and Thomas, JL and Lin, HY and McDevitt, MR and Scheinberg, DA and Sgouros, G. (2004) Engineered liposomes for potential alpha particle therapy of metastatic cancer J Nucl Med, 45, pp. 253-260.
79. Soler, RP and Francis, K and Baker, S and Ilkiewicz, FP and Khokhar, AR. (1994) Preparation and characterization of liposomes containing a lipophillic cisplatin derivative for clinical use J Microencapsul, 11, pp. 41-54.
80. Springer, CJ and Niculescu-Duvaz, I. (1997) Antibody-directed enzyme prodrug therapy (ADEPT): A review Adv Drug Deliv Rev, 26, pp. 151-172.
81. Strobel, ES and Fritschka, E. (2002) Hereditary premenopausal breast cancer J Cancer Res Treat, 25, pp. 24-2747.
82. Sugarman, SM and Perez-Soler, R. (1992) Liposomes in the treatment of malignancy: A clinical perspective Crit Rev Oncol Hematol, 12, pp. 231-242.
83. Torchilin, VP and Zhou, F and Huang, L. (1993) pH-Sensitive liposomes J Liposome Res, 3, pp. 201-205.
84. Tseng, YL and Liu, JJ and Hong, RL. (2002) Translocation of liposomes into cancer cells by cell penetrating peptides penetratin and tat: A kinetic and efficacy study Mol Pharmacol, 62, pp. 864-872.
85. Ueno, NT and Bartholomeusz, C and Xia, W and Anklesaria, P and Bruckheimer, EM and Mebel, E and Paul, R and Li, S and Yo, GH and Huang, L and et al. (2002) Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene1 Cancer Res, 62, pp. 6712-6716.
86. Vives, E and Brodin, P and Lebleu, B. (1997) A truncated HIV-1 tat protein basic domain rapidly translocates through plasma membrane and accumulates in the cell nucleus J Biol Chem, 272, pp. 16010-16017.
87. Wolff, AC. (2003) Liposomal anthracyclines and new treatment approaches for breast cancer Oncologist, 8, pp. 25-30.
88. Working, PK and Newman, MS and Sullivan, T and Yarrington, J. (1999) Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in longcirculating pegylated liposomes J Pharmacol Exp Ther, 289, pp. 1128-1133.
89. Yanagie, H and Kobayashi, H and Takeda, Y and Yoshizaki, I and Nonaka, Y and Naka, S and Nojiri, A and Shinnkawa, H and Furuya, Y and Niwa, H. (2002) Inhibition of growth of human breast cancer cells in culture by neutron capture using liposomes containing 10B Biomed Pharmacother, 56, pp. 93-99.
90. Yuan, F and Lwunig, M and Huang, SK and Berk, DA and Papahadjopoulos, D and Jain, RK. (1994) Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft Cancer Res, 54, pp. 3352-3356.
91. Zalipsky, S and Hansen, CB and Menezes, DEL and Allen, TM. (1996) Long-circulating, polyethylene glycol-grafted immunoliposomes J Control Release, 39, pp. 153-161.
92. http://www.rxlogix.com/delivery_sample02.html. Assessed on 30th Jan 06.
93. http://www.cancer.org/downloads/STT/CAFF2003BrFPWSecured.pdf. Assessed on 30th Jan 06.
94. http://www.wsws.org/articles/2003/apr2003/canc-a26.shtml. Assessed on 30th Jan 06.